

AD\_\_\_\_\_

Award Number: W81XWH-11-2-0006

TITLE: Rapid Dispersion of Polymicrobial Wound Biofilms with Depolymerase Enzymes

PRINCIPAL INVESTIGATOR: Daniel C. Nelson

CONTRACTING ORGANIZATION: University of Maryland  
College Park, MD 20742-5100

REPORT DATE: November 2012

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

<b>REPORT DOCUMENTATION PAGE</b>			<i>Form Approved</i> <i>OMB No. 0704-0188</i>		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
<b>1. REPORT DATE</b> 3 November 2012		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 4 October 2011 – 3 October 2012	
<b>4. TITLE AND SUBTITLE</b> Rapid Dispersion of Polymicrobial Wound Biofilms with Depolymerase Enzymes			<b>5a. CONTRACT NUMBER</b>		
			<b>5b. GRANT NUMBER</b> W81XWH-11-2-0006		
			<b>5c. PROGRAM ELEMENT NUMBER</b>		
<b>6. AUTHOR(S)</b> Daniel C. Nelson  <b>E-Mail:</b> nelsond@umd.edu			<b>5d. PROJECT NUMBER</b>		
			<b>5e. TASK NUMBER</b>		
			<b>5f. WORK UNIT NUMBER</b>		
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> University of Maryland College Park, MD 20742-5100			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>		
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>		
			<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>		
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> During the performance period, we successfully developed protocols to extract biofilm EPS associated with ESKAPE organisms ( <i>Enterococcus faecium</i> , <i>Staphylococcus aureus</i> , <i>Klebsiella pneumoniae</i> , <i>Acinetobacter baumannii</i> , <i>Pseudomonas aeruginosa</i> , and <i>Enterobacter</i> species). We further performed composition and linkage analysis on these samples and determined that 2 and 3-linked mannose residues constitute the major carbohydrate moiety in the EPS. In parallel, we synthesized, expressed, purified, and characterized 15 putative depolymerase enzymes by a variety of assays against static, dynamic, and mixed biofilm conditions. At least four enzymes (DSPB, NagZ, EQ, and Betty) will be advanced to safety and toxicity testing in the next performance period.					
<b>15. SUBJECT TERMS-</b> Bacteriophage, depolymerase, biofilm, extrapolymeric substance, enzyme					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>USAMRMC</b>
U	U	U	UU	25	<b>19b. TELEPHONE NUMBER</b> (include area code)


## Table of Contents

	<u>Page</u>
<b>Introduction.....</b>	<b>1</b>
<b>Body.....</b>	<b>2</b>
<b>Key Research Accomplishments.....</b>	<b>20</b>
<b>Reportable Outcomes.....</b>	<b>20</b>
<b>Conclusion.....</b>	<b>21</b>
<b>References.....</b>	<b>21</b>
<b>Appendices.....</b>	<b>22</b>

## INTRODUCTION:

There is a critical need for basic research to discover new methods that would improve the outcomes of soldiers who incur battlefield wounds. Initially, most war wounds are colonized by Gram-positive bacteria. However, after initial stabilization and surgery, residual infections in open wounds are characterized by predominantly Gram-negative bacteria including *Acinetobacter baumannii-calcoaceticus* complex, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. Additionally, wounded soldiers have a very high rate of hospital-acquired infections by such pathogens as *Staphylococcus aureus*. Thus, war wounds remain susceptible to infection from the time of injury through subsequent surgery, therapy, and rehabilitation and often contain multiple bacterial species. Moreover, each of these organisms has different resistance patterns to antibiotics, further limiting treatment options. Often, even broad-spectrum antibiotics are not sufficient to eradicate all of the organisms contained within a wound.

While bacterial pathogenesis mechanisms, virulence factors, and antimicrobial resistance vary greatly between pathogens associated with war wounds, one common trait shared by all is the ability to colonize wounds as a biofilm (see figure). Biofilms are formed when planktonic bacteria (i.e., free, individual cells) adsorb onto a wound surface and form multi-cellular colonies (figure, stage 1).



Once the colonies become established, phenotypic changes cause them to secrete polysaccharides that serve as the backbone for the biofilm (figure, stage 2 and 3). Non-cellular components and debris, including additional carbohydrates, proteins, lipids, and nucleic acids, become entangled in the polysaccharide backbone and constitute the extrapolymeric substance (EPS) or “slime” layer of a biofilm (figure, stage 4). Significantly, the superstructure of the biofilm is known to protect internal bacteria from antimicrobials, antibodies, and circulating immune cells (figure, stage 5). *Thus, approaches that disrupt or dissolve the biofilm superstructure of polymicrobial infections would offer a therapeutic avenue to reduce the morbidity and mortality associated with war wounds by “re-sensitizing” the bacteria to antibiotics and the soldier’s immune system.*

To accomplish this goal, we will use special enzymes called depolymerases. Depolymerases are normally found on the surface of bacterial viruses (i.e. bacteriophage) where they function to dissolve the EPS layer on naturally occurring biofilms allowing the phage to invade the bacterial cell. We plan to identify and test many such depolymerases to find the best enzyme, or cocktail of enzymes, that will dissolve biofilms associated with the bacteria that infect war wounds. Although the depolymerases do not directly kill the bacteria, it is believed that dissolution of the biofilm protective layer will allow common antibiotics or the immune system to clear the infection.

## **BODY:**

Note: This is the second annual report for DM102823. The first annual report covered the following aims:

- Aim 1. Task 1. IACUC review
- Aim 1. Task 2. Bioinformatic analysis.
- Aim 1. Task 3. Synthesize depolymerases.
- Aim 1. Task 4. Obtain phage.
- Aim 1. Task 5. Clone depolymerases.
- Aim 1. Task 6. Express and purify depolymerases.
- Aim 2. Task 1. Purify biofilm EPS.

This annual report covers the following aims:

- Aim 2. Task 1. Purify biofilm EPS.
- Aim 2. Task 2. Glycosyl composition.
- Aim 2. Task 3. Glycosyl linkage.
- Aim 3. Task 1. Static biofilms.
- Aim 3. Task 2. Dynamic biofilms.
- Aim 3. Task 3. Polymicrobial biofilms.

*Aim 2. Task 1. Purify biofilm EPS.*

*Aim 2. Task 2. Glycosyl composition.*

*Aim 2. Task 3. Glycosyl linkage.*

Since we selected strains that readily formed biofilms, establishing appropriate biofilm conditions was fairly simple. However, we spent considerable time developing and validating a novel method to extract the high molecular weight polysaccharide that constitutes the structural backbone of the biofilm EPS. Numerous protocols describe extraction methods for bacterial polysaccharide capsule as well as covalently attached surface polysaccharides, but very few are specific for biofilm EPS. Of those that are published, none allowed for the level of purification we required for our analysis. In the end, we took elements from three prior publications, combined with a gel filtration step in order to achieve the purity required. Below is a brief summary of our EPS polysaccharide purification flow chart.

Liu and Fang (2002) “Extraction of extracellular polymeric substances (EPS) of sludges”.  
Journal of Biotechnology 95:249–256.

Oliveira, Marques, and Azeredo (1999) “Purification of polysaccharides from a biofilm matrix by selective precipitation of proteins”. Biotechnology Techniques, 13:391-393.

Sofia Andersson (2009) “Characterization of bacterial biofilms for wastewater treatment”.  
Ph.D. Thesis, Royal Institute of Technology, School of Biotechnology, Stockholm, Sweden

- Grow bacteria for several days to develop thick “sludge” biofilms

- Add 60 ul formaldehyde (36.5%) per 10 mls of “sludge” at 4C for 1 hour
- 4 mls 1N NaOH per 10 mls, 4C, 3 hours to extract bulk EPS from cells
- 20,000G centrifugation x 20 min, 4C
- Filter supernatant through 0.2 micron filter (may have to add DNase to decrease viscosity from released nucleic acids).
- Dialyze against water 3500 MWCO membrane, 4C, 24 hours
- 20% TCA to precipitate protein as well as DNA, but leaves polysaccharides in the supernatant.
- 190-200 proof ethanol is used to precipitate polysaccharides away from lipids.
- Resuspend pellet and dialyze against water 3500 MWCO membrane, 4C, 24 hours
- Lyophilize overnight
- S-200 gel filtration to separate high molecular weight sugars from mono- and di-saccharides
- Phenol sulfuric acid assay to detect sugars in fractions
- Pool high molecular weight fractions.
- Dialyze against water 3500 MWCO membrane, 4C, 24 hours
- Lyophilize overnight.
- Samples ready for composition and linkage analysis.

The above protocol takes several weeks per sample. As a side note, since we had to develop such a novel extraction protocol that was not previously published, we are planning to submit it as a standalone protocol manuscript rather than as part of a larger manuscript.

The following samples were purified and were subjected to both composition and linkage analysis.

Sample ID: BAA1605

Source: EPS carbohydrate from *Acinetobacter baumannii*  
04/10/12 ~7 mg

Sample ID: BAA1878

Source: EPS carbohydrate from *Acinetobacter baumannii*  
04/10/12 ~5 mg

Sample ID: 700831

Source: EPS carbohydrate from *Klebsiella pneumoniae*  
04/10/12 ~5 mg

Sample ID: 700603

Source: EPS carbohydrate from *Klebsiella pneumoniae*  
04/10/12 ~23 mg

Sample ID: 700829

Source: EPS carbohydrate from *Pseudomonas aeruginosa*  
04/10/12 ~9 mg

Sample ID: 700888

Source: EPS carbohydrate from *Pseudomonas aeruginosa*

04/10/12 ~5 mg

The completed composition analysis for six different strains shown below:

<b>700829 (<i>P. aeruginosa</i>)</b>		
<b>Glycosyl residue</b>	<b>Mass (<math>\mu\text{g}</math>)</b>	<b>Mol %<sup>1</sup></b>
Arabinose (Ara)	3.7	1.6
Rhamnose (Rha)	2.7	1.0
Fucose (Fuc)	0.5	0.2
Xylose (Xyl)	1.0	0.4
Galacturonic acid (GalA)	2.1	0.7
Mannose (Man)	253.4	89.5
Galactose (Gal)	8.5	3.0
Glucose (Glc)	10.3	3.6
$\Sigma$	282.0	100.0

<b>BAA-1605 (<i>A. baumannii</i>)</b>		
<b>Glycosyl residue</b>	<b>Mass (<math>\mu\text{g}</math>)</b>	<b>Mol %<sup>1</sup></b>
Arabinose (Ara)	0.8	1.1
Rhamnose (Rha)	0.1	0.1
Fucose (Fuc)	0.1	0.1
Xylose (Xyl)	0.3	0.4
Galacturonic acid (GalA)	1.9	2
Mannose (Man)	73.9	84
Galactose (Gal)	3.5	4
Glucose (Glc)	7.0	7.9
N-Acetyl Glucosamine (GlcNAc)	0.5	0.4
$\Sigma$	88.0	100

<b>700888 (<i>P. aeruginosa</i>)</b>		
<b>Glycosyl residue</b>	<b>Mass (<math>\mu\text{g}</math>)</b>	<b>Mol %<sup>1</sup></b>
Arabinose (Ara)	2.5	2.4
Rhamnose (Rha)	1.6	1.3
Fucose (Fuc)	0.3	0.2
Xylose (Xyl)	0.6	0.5
Galacturonic acid (GalA)	1.1	0.8
Mannose (Man)	109.2	84.3
Galactose (Gal)	4.8	3.7
Glucose (Glc)	8.8	6.8
$\Sigma$	128.8	100

<b>BAA-1878 (<i>A. baumannii</i>)</b>		
<b>Glycosyl residue</b>	<b>Mass (<math>\mu\text{g}</math>)</b>	<b>Mol %<sup>1</sup></b>
Arabinose (Ara)	1.0	0.5
Rhamnose (Rha)	0.1	0
Xylose (Xyl)	0.3	0.2
Galacturonic acid (GalA)	2.5	1
Mannose (Man)	181.2	79.3
Galactose (Gal)	30.3	13.2
Glucose (Glc)	10.3	4.5
N-Acetyl Glucosamine (GlcNAc)	3.5	1.3
$\Sigma$	229.1	100

<b>700831 (<i>K. pneumonia</i>)</b>		
<b>Glycosyl residue</b>	<b>Mass (<math>\mu\text{g}</math>)</b>	<b>Mol %<sup>1</sup></b>
Arabinose (Ara)	2.3	1.5
Rhamnose (Rha)	16.3	10
Fucose (Fuc)	0.4	0.3
Xylose (Xyl)	0.7	0.5
Galacturonic acid (GalA)	18.9	9.8
Mannose (Man)	68.4	38.3
Galactose (Gal)	14.0	7.8
Glucose (Glc)	55.5	31.1
N-Acetyl Glucosamine (GlcNAc)	1.5	0.7
$\Sigma$	178.0	100

700603 ( <i>K. pneumoniae</i> )		
Glycosyl residue	Mass ( $\mu\text{g}$ )	Mol % <sup>1</sup>
Rhamnose (Rha)	54.8	27
Glucuronic Acid (GlcA)	11.4	5
Galacturonic acid (GalA)	6.1	2.5
Mannose (Man)	110.8	49.4
Galactose (Gal)	32.4	14.4
Glucose (Glc)	2.8	1.3
N-Acetyl Glucosamine (GlcNAc)	2.1	0.8
$\Sigma$	220.5	99.9

### Linkage analysis

For glycosyl linkage analysis, the sample was permethylated, depolymerized, reduced, and acetylated; and the resulting partially methylated alditol acetates (PMAAs) analyzed by gas chromatography-mass spectrometry (GC-MS) as described by York *et al* (1985) *Methods Enzymol.* 118:3-40.

Initially, dry sample was suspended in about 300  $\mu\text{l}$  of dimethyl sulfoxide and placed on a magnetic stirrer for 5 days. The sample was then permethylated by the method of Ciukanu and Kerek (1984) *Carbohydr. Res.* 131:209. The sample was subjected to the NaOH base then methyl iodide was added. The base and more methyl iodide was added again. This addition of more methyl iodide and NaOH base was to insure complete methylation of the polymer. Following sample workup, the permethylated material was hydrolyzed using 2 M trifluoroacetic acid, reduced with NaBD<sub>4</sub>, and acetylated using acetic anhydride/trifluoroacetic acid. The resulting PMAAs were analyzed on a Hewlett Packard 5975C GC interfaced to a 7890A MSD (mass selective detector, electron impact ionization mode); separation was performed on a 30m Supelco 2330 bonded phase fused silica capillary column.

**Note:** The resulted spectrum showed 2-linked mannopyranosyl residue and 3-linked mannopyranosyl residues eluting together. Therefore we analyzed the sample again in an Agilent 6890N GC interfaced to a 5975B MSD, using a Supelco EC-1 fused silica capillary column (30m  $\times$  0.25 mm ID) to be able to distinguish these two residues. The ratio of 2-mannose and 3-mannose were thus determined from the resulting spectra and the percentage of peak area corresponding to the linkage analysis was calculated.

**Results:****700603**

<b>GLYCOSYL RES</b>	<b>PK AREA%</b>
terminally linked rhamnopyranosyl residues (t-man)	1.6
2-linked rhamnopyranosyl residue (2-Rha)	7.3
terminally linked mannopyranosyl residues (t-man)	1.3
terminal linked galactopyranosyl residue (t-gal)	0.3
2-linkedmannopyranosyl (2-Man)	40.1
3-linked mannopyranosylresidue (3-Man)	15.4
3-linked galactopyranosyl residue (3-Gal)	18.2
4-linked glucopyranosyl residue (4-Glc)	0.4
2,3-linked mannopyranosyl residue (2,3-man)	15.4

**700829**

<b>GLYCOSYL RES</b>	<b>Peak Area (%)</b>
terminally linked mannopyranosyl residues (t-man)	23.3
terminal linked galactopyranosyl residue (t-gal)	0.1
4 linked arabinopyranosyl residue (4-Ara)	0.2
3-linked glucopyranosyl residue (3-Glc)	1.2
2-linkedmannopyranosyl (2-Man)	20.6
3-linked mannopyranosylresidue (3-Man)	16.7
6-linked mannopyranosyl residue (6-Man)	1.4
6-linked glucopyranosyl residue (6-Glc)	0.6

4-linked galactopyranosyl residue (4-Gal)	1.2
4-linked glucopyranosyl residue (4-Glc)	0.2
2,3-linked mannopyranosyl residue (2,3-man)	1.3
3,6-linked mannopyranosyl residue (3,6-Man)	0.6
2,6-linked mannopyranosyl residue (2,6-man)	32.3
3,6-linked galacopyranosyl residue (3,6-Gal)	0.3

### 700831

GLYCOSYL RES	PK AREA%
terminally linked rhamnopyranosyl residues (t-Rha)	0.3
terminally linked mannopyranosyl residues (t-man)	10.5
terminallylinked glucopyranosylresidue (t-Glc)	1.2
4 linked arabinopyranosyl residue (4-Ara)	0.2
3-linked glucopyranosyl residue (3-Glc)	14.4
2-linkedmannopyranosyl (2-Man)	13.8
3-linked mannopyranosylresidue (3-Man)	5.2
2-linked hexafuranosyl residue (2-hexf)	12.2
6-linked mannopyranosyl residue (6-Man)	1.2
6-linked glucopyranosyl residue (6-Glc)	0.4
4-linked galactopyranosyl residue (4-Gal)	0.2
4-linked glucopyranosyl residue (4-Glc)	0.4
2,3-linked mannopyranosyl residue (2,3-man)	0.5
2,3,4-linked mannopyranosyl residue (2,3-man)	11.6
3,6-linked mannopyranosyl residue (3,6-Man)	0.4

2,6-linked mannopyranosyl residue (2,6-man)	16.1
4,6-linked glucopyranosyl residue (4,6-Glc)	11.4

## 700888

GLYCOSYL RES	PK AREA%
terminally linked mannopyranosyl residues (t-man)	27.4
terminal linked galactopyranosyl residue (t-gal)	0.2
4 linked arabinopyranosyl residue (4-Ara)	0.2
2-linked xylopyranosyl residue (2-Xyl)	0.1
3-linked glucopyranosyl residue (3-Glc)	1.3
2-linkedmannopyranosyl (2-Man)	19.3
3-linked mannopyranosylresidue (3-Man)	16.0
3-linked galactopyranosyl residue (3-Gal)	0.3
4-linked mannopyranosyl residue (4-Man)	0.4
6-linked mannopyranosyl residue (6-Man)	1.6
6-linked glucopyranosyl residue (6-Glc)	0.7
4-linked galactopyranosyl residue (4-Gal)	1.6
4-linked glucopyranosyl residue (4-Glc)	0.4
2,3-linked mannopyranosyl residue (2,3-man)	1.2
3,6-linked mannopyranosyl residue (3,6-Man)	0.7
2,6-linked mannopyranosyl residue (2,6-man)	28.5
3,6-linked galacopyranosyl residue (3,6-Gal)	0.2

**BAA1605**

GLYCOSYL RES	PK AREA%
terminally linked mannopyranosyl residues (t-man)	25.4
2-linkedmannopyranosyl (2-Man)	20.2
3-linked mannopyranosylresidue (3-Man)	16.5
6-linked mannopyranosyl residue (6-Man)	2.2
6-linked glucopyranosyl residue (6-Glc)	1.3
4-linked galactopyranosyl residue (4-Gal)	1.1
3,6-linked galacopyranosyl residue (3,6-Gal)	0.8
2,6-linked mannopyranosyl residue (2,6-man)	32.5

**BAA1878**

GLYCOSYL RES	PK AREA%
terminally linked mannopyranosyl residues (t-man)	27.4
terminal linked galactopyranosyl residue (t-gal)	0.2
4 linked arabinopyranosyl residue (4-Ara)	0.2
2-linked xylopyranosyl residue (2-Xyl)	0.1
3-linked glucopyranosyl residue (3-Glc)	1.3
2-linkedmannopyranosyl (2-Man)	19.2
3-linked mannopyranosylresidue (3-Man)	15.8
3-linked galactopyranosyl residue (3-Gal)	0.3
4-linked mannopyranosyl residue (4-Man)	0.4
6-linked mannopyranosyl residue (6-Man)	1.6
6-linked glucopyranosyl residue (6-Glc)	0.7

4-linked galactopyranosyl residue (4-Gal)	1.6
4-linked glucopyranosyl residue (4-Glc)	0.4
2,3-linked mannopyranosyl residue (2,3-man)	1.2
3,6-linked glucopyranosyl residue (3,6-Glc)	0.7
2,6-linked mannopyranosyl residue (2,6-man)	28.5
3,6-linked galacopyranosyl residue (3,6-Gal)	0.2


**Comments:**

Linkage results indicate that all samples mainly consist of terminally linked mannopyranosyl residue (t-man), 2-linked mannopyranosyl (2-Man) and 3-linked mannopyranosyl residue (3-Man). 2,6-linked mannopyranosyl residue (2,6-man) were found in all samples except **700603**. Other linkage residues of galactose, glucose and mannose were also found in all samples. Small amount of terminally linked rhamnopyranosyl residue (t-Rha), 2-linked rhamnopyranosyl residue (2-Rha) were found in sample **700603**. 2-linked hexafuranosyl residue (2-hexf) was only found in sample **700831**. 4-linked arabinopyranosyl residue (4-Ara) was found in **BAA1878, 700831, 700888 and 700829**. 2-linked xylopyranosyl residue (2-Xyl) was only found in sample **700888**.


Surprisingly, all biofilms contained a very high content of mannose. In addition to composition analysis above, linkage analysis of the glycosyl units was also performed by GC/MS on permethylated, depolymerized, reduced, and acetylated EPS samples. As expected, a high percentage of all EPS linkages were found to include mannose. Linkages that composed 10% or more of all linkages of at least one EPS sample are given in the table below. (PA is *Pseudomonas aeruginosa*, KP is *Klebsiella pneumonia*, and AB is *Acinetobacter baumannii*).

Glycosyl residue	Peak Area (%)					
	PA		KP		AB	
	700829	700888	700603	700831	1605	1878
t-Man	23.3	27.4	1.3	10.5	25.4	27.4
2-Man	20.6	19.3	40.1	13.8	20.2	19.2
3-Man	16.7	16	15.4	5.2	16.5	15.8
2,6-Man	32.3	28.5	N/A	16.1	32.5	28.5
3-Glc	N/A	N/A	N/A	14.4	N/A	N/A
2-Hexf	N/A	N/A	N/A	12.2	N/A	N/A
2,3-Man	N/A	N/A	15.4	N/A	N/A	N/A
2,3,4-Man	N/A	N/A	N/A	11.6	N/A	N/A
4, 6-Glc	N/A	N/A	N/A	11.4	N/A	N/A
3-Gal	N/A	N/A	18.2	N/A	N/A	N/A

### Major EPS Linkages shared between strains



A high percentage of 1-2 linked mannose was found in all 6 tested ESKAPE strains' EPS




Linkage analysis data can be used to get a rough idea of the overall structure of a particular exopolysaccharide. Above is a representation of the likely structure of sample 700826 (mass spectrometry would be necessary confirm the exact structure).

Confirmation of high mannose content was achieved by assaying lectin-biofilm binding. Since all strains contained a high proportion of mannose 1-3 or mannose 2-6 linkages, the fluorescently-labeled lectin HHA (provided by EY Laboratories), was chosen. HHA binds specifically to  $\alpha$ 1-3 and  $\alpha$ 1-6 mannosyl residues and likely  $\alpha$ 2-6 residues as well (our data).


Biofilms were grown for 4 days in 96-well plates, washed 3 times with PBS, incubated with 10 ug HHA for 15 min, and then washed 3 more times. Fluorescence at 517 nm was observed using an excitation wavelength of 472 nm. When necessary, normalization to account for the amount of biofilm development was done using crystal violet staining.

## Lectin binding to ESKAPE biofilms



Because many biofilms possess  $\alpha$ 1-2 linked mannose residues, we purchased a commercial mannosidase  $\alpha$ 1-2 mannosidase from New England Biolabs and evaluated its anti-biofilm properties. Preliminary data (figure, next page) suggests that this enzyme cleaves man  $\alpha$ 1-2 linkages may disperse biofilms of sample 1605 according to a bacterial CFU release assay. In this assay, biofilm wells are treated with putative depolymerase enzymes or buffer, incubated, and the supernatant is serially diluted and plated to enumerate bacterial colony forming units (CFU) present. An active enzyme will digest the biofilm matrix and increase the CFUs released to the supernatant. Research into the reproducibility of this result as well as the effect of mannosidases on other ESKAPE biofilms' dispersal is ongoing.

## CFU release due to mannosidase treatment



Aim 3. Task 1. Static biofilms.

Aim 3. Task 2. Dynamic biofilms.

Aim 3. Task 3. Polymicrobial biofilms.


In parallel with the characterization of the EPS biofilm of Aim 2, we continued to develop and evaluate our top depolymerase enzymes on static, dynamic, and polymicrobial biofilms (Aim 3). Currently, our top depolymerases are DSP, SF6, and CBA\_120, however, we do have more in the pipeline that have just recently been characterized. For these experiments, we utilized three different methods to demonstrate depolymerase activity. For all methods, we first grew static biofilms in 96 well plates for 24 hours. Examples of data collected from each method and a summary chart of our current findings is below.

1. Biomass Eradication Assay. In this assay, biofilm wells are treated with putative depolymerase enzymes or buffer, incubated, and the remaining biofilm biomass is stained with 0.1% crystal violet. The crystal violet can be quantified by extraction in 1% SDS and read on a spectrophotometer at 590 nm. An active enzyme will decrease the crystal violet staining compared to controls.
2. Bacterial CFU Release Assay. In this assay, biofilm wells are treated with putative depolymerase enzymes or buffer, incubated, and the supernatant is serial diluted and

plated to enumerate bacterial colony forming units (CFU) present. An active enzyme will digest the biofilm matrix and increase the CFUs released to the supernatant.

3. Carbohydrate Release Assay. In this assay, biofilm wells are treated with putative depolymerase enzymes or buffer, incubated, and the supernatant is assayed for total carbohydrate content by the phenol sulfuric acid method (Dubois, M., K. A., Gilles, J. K. Hamilton, P. A., Rebers and F. Smith, Anal. Chem. 28, 350 (1956)). An active enzyme will digest the biofilm matrix and increase total carbohydrate content of the supernatant.

Below is just one sample of data against static biofilms:




- 700831 known biofilm producer of *Klebsiella pneumonia*
- 1605 multi-drug resistant isolate of *Acinetobacter baumannii* from Afghanistan
- 1878 *Acinetobacter baumannii* from a burn patient
- 68 Enteric organism with expanded spectrum beta-lactamase resistance (i.e., ESBL)
- 101 Methicillin-resistant *Staphylococcus aureus* (i.e., MRSA)
- 1143 Enterobacteria with AmpC mediated ESBL

The panel on the left depicts bacterial counts in the supernatants of static biofilms treated with PBS, or two depolymerases, DSP and Betty. If the depolymerases break down the biofilm, we would expect to see an increase in colony counts of the biofilm supernatant, which we see for *Acinetobacter baumannii*, an Enteric organism, and a MRSA strain. The panel on the right depicts a similar test of static biofilm bacteria, except we stained the remaining biofilm with crystal violet and measured the amount of residual biomass (which intercalates crystal violet in the biofilm). As can be seen, the depolymerases work well with the MRSA biofilm, but the

results are not as clear cut with the other biofilms which do not appear to take us as much crystal violet in the control wells. A picture of the actual MRSA wells is below to illustrate the anti-biofilm properties of Dsp.

### Dsp Treatment

### PBS Treatment



Thus it appears that supernatant colony counts are more quantitative of depolymerase activity than crystal violet, which displays wide variation in staining properties between biofilms of different bacterial species.

Below is a chart that summarizes our finding for DSP, SF6, and CBA\_120 from the past several months:

ATCC #	Organism	Biomass Reduction	Bacterial CFU Release	Carbohydrate Reslease
1605	<i>Acinetobacter baumannii</i>		DSP	DSP
1878	<i>Acinetobacter baumannii</i>		DSP/CBA_120/SF6	
35218	<i>E.Coli</i>		DSP/CBA_120	
700728	<i>E. coli O157:H7</i>		CBA_120/SF6	DSP/CBA_120/SF6
43894	<i>E. coli O157:H7</i>			DSP/CBA_120/SF6
1143	<i>Enterobacter</i>		DSP	DSP/CBA_120
68	<i>Enterobacter</i>		DSP/CBA_120	CBA_120
700603	<i>Klebsiella pneumonia</i>		DSP/CBA_120	DSP/CBA_120/SF6
10145	<i>Pseudomonas aeruginosa</i>		DSP/CBA_120	
27853	<i>Pseudomonas aeruginosa</i>	DSP/CBA_120/SF6	DSP/Betty/SF6	
700829	<i>Pseudomonas aeruginosa</i>		CBA_120	
101	<i>Staphylococcus aureus</i>	DSP/CBA_120	DSP/CBA_120	


Our proposal called for evaluation of 15-20 potential depolymerases overall. However, we did not start out with this number. Instead, we only evaluated a couple so we could select future depolymerases based on knowledge gained from the first characterized depolymerases (i.e., it is an iterative process). In our early reports, we were quite keen on tail spike proteins for their putative depolymerase activity. However, we found this class of protein to be very species-specific and only possessed a low level of depolymerase activity. Recent enzymes added to the

list include classes of lyases and glucuronidases, which correspond to major bonds found in biofilm EPS. Below is a chart summarizing our current progress. 15 putative depolymerases have been synthesized, 11 have been cloned and transformed into expression systems, and 8 have been purified and partially characterized. The lead candidates will be assessed in safety and toxicity testing (Q9-Q12).



Gene/Art name	Characteristics	Target EPS	Predicted MW (kDa)	Cloning into pBAD24	Transformation into BL21(DE3)	Expression/Characterization
Dispersin B	Known depolymerase, active against Staph spp. and E. coli	Staph spp., E. coli	37	Y	Y	Y
SL-DspB	Staphylococcal homolog of Dispersin B	Staph spp., E. coli	35	Y	Y	Y
SF6	Known tailspike	E. coli	65.8	Y	Y	Y
CPA_120_160c	Putative CPA_120 myophage tail-spike	E. coli O157:H7	81.96	Y	Y	Y
DSP-NW	Related to DspB, from Neisseria sp.	Staph spp., E. coli	57.9	Y	Y	Y
DSP-AA	Related to DspB, from Aggregatibacter sp.	Staph spp., E. coli	46.7	Y	Y	Y
Lyase-U	Related to Klebsiella alginate lyase, from uncultured	P. aeruginosa	36.2	Y	Y	Y
Lyase-SD	Related to Klebsiella alginate lyase, from S. degradans	P. aeruginosa	57.1	Y	Y	Y
Lyase-MB	Microbulbifer protein related to Klebsiella alg lyase	P. aeruginosa	39	Y	Y	TBD
Lyase-PA	Related to Klebsiella alginate lyase, from P. aeruginosa	P. aeruginosa	41.6	Y	Y	TBD
Lyase-SM	Related to Pseudomonas alginate lyase, from S. maltophilia	P. aeruginosa	37.7	Y	Y	TBD
Gluc-Eq	Related to E. coli glucuronidase, from S. equi	K. pneumonia	69.2	TBD	TBD	TBD
Gluc-NH	Related to E. coli glucuronidase, from N. haematocca	K. pneumonia	68.9	TBD	TBD	TBD
Gluc-FO	Related to E. coli glucuronidase, from F. oxysporum	K. pneumonia	69.1	TBD	TBD	TBD
NagZ-AB	Related to E. coli NagZ, sequenced from Acinetobacter	Acinetobacter baumannii	39	TBD	TBD	TBD


We have performed dozens and dozens of experiments with the above enzymes in static, dynamic, and mixed biofilms using the biomass eradication assay, the bacterial CFU release assay, and the carbohydrate release assay, also known as the Elson Morgan assay. We have concluded that the carbohydrate release (Elson Morgan) assay gives us the most reproducible results for depolymerase enzymatic activity. Below is just a brief sample of our results with some of the enzymes listed above. Clearly, different enzymes display efficacy for certain ESKAPE strains. The best enzymes will be forwarded to safety and toxicity testing in Q9-Q12.

### Elson Morgan-amino (normalized to PBS)



## Elson Morgan-amino (normalized to PBS)





### KEY RESEARCH ACCOMPLISHMENTS:

- Extracted EPS from biofilms of ESKAPE organisms
- Performed composition analysis for EPS from ESKAPE organisms
- Performed linkage analysis for EPS from ESKAPE organisms
- Successfully synthesized, expressed, and purified and evaluated ~15 putative depolymerase enzymes
- Assayed depolymerase enzymes in static, dynamic, and polymicrobial biofilms

### REPORTABLE OUTCOMES:

Some aspects of our preliminary data and/or overall strategy have been presented at the following meetings/symposia during the past year:

1. Viruses of Microbes International Conference. Brussels, Belgium. Keynote symposium speaker. “X-ray Crystal Structure of PlyC, a Novel Enzybiotic” (July, 2012).

2. National Institute for Standards and Technology, Gaithersburg, MD. Invited Speaker for the Metrology of Microbial Systems Seminar Series. "Exploiting Bacteriophage Endolysins for Therapeutic and Diagnostic Use against Bacterial Pathogens" (November, 2011).
3. 3<sup>rd</sup> Annual Biomedical Sciences Day, The Universities at Shady Grove, Rockville, MD. "Evaluation of Bacteriophage Encoded Enzymes as Novel Therapeutic Agents against Biofilm-associated Infections" 1<sup>st</sup> Place Poster Presentation Award to Emilija Renke. (November, 2011)
4. University of Georgia, Athens, GA. Distinguished Alumni Marquee Speaker, Department of Biochemistry and Molecular Biology. "Structure/Function Studies on Enzybiotics" (October, 2011).
5. The 14<sup>th</sup> Annual Undergraduate Research Symposium in the Chemical and Biological Sciences. Baltimore, MD. "Utilization of Bacteriophage-Encoded Enzymes for the Vigorous Disruption of Biofilm Matrices" 1<sup>st</sup> Place Student Poster Award to Emilija Renke. (October, 2011)

## **CONCLUSION:**

We have successfully analyzed the carbohydrate composition and linkage analysis of biofilm EPS for ESKAPE organisms and found that mannose is the predominant carbohydrate associated with the EPS. As such, we are investigating the anti-biofilm properties of mannosidases. In parallel, we have expressed and characterized ~15 putative depolymerase enzymes. Although there is species specific heterogeneity, several of these enzymes show broad anti-biofilm activity. these include DSPB, NagZ, EQ, and Betty. We consider these four enzymes our "lead compounds" at this point, although we continue to evaluate all 15 enzymes.

## **REFERENCES:**

- Casjens SR and Thuman-Commike PA. Evolution of mosaically related tailed bacteriophage genomes seen through the lens of phage P22 virion assembly. *Virology*. 2011 Mar 15;411(2):393-415. Epub 2011 Feb 18.
- Hanlon GW, Denyer SP, Olliff CJ, Ibrahim LJ: Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through *Pseudomonas aeruginosa* biofilms. *Appl Environ Microbiol* 2001, 67(6):2746-2753.
- Hughes KA, Sutherland IW, Clark J, Jones MV: Bacteriophage and associated polysaccharide depolymerases--novel tools for study of bacterial biofilms. *J Appl Microbiol* 1998, 85(3):583-590.
- Kaplan JB: Therapeutic potential of biofilm-dispersing enzymes. *Int J Artif Organs* 2009, 32(9):545-554.

Liu, H, Fang, H.H.P. Extraction of extracellular polymeric substances (EPS) of sludges. *J. Biotechnol.* 2002, 95:249–256.

Oliveira, R., Marques, F., and Azeredo, J. Purification of polysaccharides from a biofilm matrix by selective precipitation of proteins. *Biotechnol. Techniques*, 1999. 13:391-393.

Otto M: Bacterial evasion of antimicrobial peptides by biofilm formation. *Current Topics in Microbiology and Immunology* 2006, 306:251-258.

Xavier JB, Picioreanu C, Rani SA, van Loosdrecht MC, Stewart PS: Biofilm-control strategies based on enzymic disruption of the extracellular polymeric substance matrix--a modelling study. *Microbiology* 2005, 151(Pt 12):3817-3832.

**APPENDICES:** None.

**SUPPORTING DATA:**

Figures and figure legends are contained within the body of the text above.